Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07658339 HSK-39004 Pulmonary Disease, Chronic Obstructive Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658339, evaluating HSK-39004 in Pulmonary Disease, Chronic Obstructive: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Acetaminophen/Magnesium Oxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Acetaminophen/Magnesium Oxide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07661342 Radiation Therapy Dupuytren Contracture Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07661342, evaluating Radiation Therapy in Dupuytren Contracture: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Acetaminophen/Vitamin B2 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Acetaminophen/Vitamin B2: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07659574 UBT-251 Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659574, evaluating UBT-251 in Diabetes Mellitus, Type 2: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07659678 64CU-DOTA-ECL1i Recurrent Squamous Cell Carcinoma of the Head and Neck Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07659678, evaluating 64CU-DOTA-ECL1i in Recurrent Squamous Cell Carcinoma of the Head and Neck: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Ibuprofen/Magnesium Oxide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Ibuprofen/Magnesium Oxide: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
ChiCTR2600127006 Blinatumomab Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into ChiCTR2600127006, evaluating Blinatumomab in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Meloxicam/Rizatriptan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Meloxicam/Rizatriptan: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
NCT07658976 Doxycycline Hyclate HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07658976, evaluating Doxycycline Hyclate in HIV Infections: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
NCT07663903 Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) Hemophilia A Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
A focused 2026 clinical landscape deep dive into NCT07663903, evaluating Recombinant human coagulation factor VIII-Fc fusion protein (Gensciences) in Hemophilia A: trial design, endpoint strategy, sponsor context, benchmark readouts and development white space.
Latest Hotspot
8 min read
Atezolizumab/Hyaluronidase-tqjs Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
21 July 2026
Atezolizumab/Hyaluronidase-tqjs: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.